i
This Document Has Been Replaced By: Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP)
Superseded
This Document Has Been Replaced By: Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP)
Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
-
March 12, 2010
Source: MMWR. Morbidity and mortality weekly report. 2010; 59(9):273.
[PDF-1.59 MB]
Details:
-
Alternative Title:MMWR. Morbidity and mortality weekly report
-
Corporate Authors:
-
Description:On February 19, 2010, the Food and Drug Administration (FDA) licensed a quadrivalent meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics). MenACWY-CRM is licensed as a single dose for use among persons aged 11-55 years. The Advisory Committee on Immunization Practices (ACIP) reviewed data from prelicensure clinical trials on the safety and immunogenicity of MenACWY-CRM. This report summarizes the approved indications for MenACWY-CRM and provides guidance from ACIP for its use. The following guidance for use of MenACWY-CRM is consistent with licensed indications and ACIP recommendations for meningococcal conjugate vaccines.
-
Subject:
-
Pubmed ID:20224545
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
No Additional Files
More +
Email
CDC-INFO
